Bayer Health Care Clinical Study Report (2009) A Pivotal, Placebo Controlled, Phase III Study to Compare Efficacy and Tolerability of a Fixed Combination, Containing 500 mg ASA and 30 mg Pseudoephedrine, in Comparison to Its Single Components in Patients with Sore Throat and Nasal Congestion. Report No. CC-03008.

has been cited by the following article:

• TITLE: Aspirin plus Pseudoephedrine (Aspirin Complex) for the Treatment of Symptoms of Upper Respiratory Tract Infection

  AUTHORS: Michael Voelker, Ronald Eccles, Uwe Gessner

  KEYWORDS: Aspirin, Acetylsalicylic Acid, Pseudoephedrine, Dissolution, Pharmacokinetic, Upper Respiratory Tract Infection, Clinical Studies

  JOURNAL NAME: Open Journal of Respiratory Diseases, Vol.7 No.1, February 7, 2017

  ABSTRACT: Upper respiratory tract infections or common colds are a multi-symptom disease which is usually symptomatically treated with fixed dose multi-active ingredient medicinal products which are commonly used as non-prescription and over the counter. However, the active ingredients combined require a particular and clinically sound justification. Analgesics and decongestant can be combined to treat simultaneously the prominent symptoms cold-related pain (e.g. headache, muscle aches and pains), fever, inflammationand nasal/sinus congestion. This overview provides a summary of the evidence supporting the combination of acetylsalicylic acid (aspirin) and pseudoephedrine available in the common cold product Aspirin® Complex.